In a landmark decision that promises to reshape the global approach to viral hepatitis, the European Commission has granted approval for AbbVie’s Maviret (glecaprevir/pibrentasvir) for the treatment of both acute and chronic hepatitis C virus (HCV) infection. This regulatory milestone marks a significant departure from the traditional "wait-and-see" clinical paradigm, enabling physicians to initiate curative therapy the moment a patient tests positive for the virus, rather than waiting for the infection to transition into a chronic state.
For years, the medical community has operated under the assumption that patients should be monitored to see if their bodies would spontaneously clear the HCV infection. This strategy was not merely a clinical choice but often a requirement dictated by restrictive treatment indications and bureaucratic hurdles. By expanding the label for Maviret, AbbVie has effectively removed these barriers, bringing regulatory approval into alignment with modern clinical goals: the total elimination of Hepatitis C as a public health threat.
The Shift: From Vigilance to Immediate Intervention
The historical reliance on a "watchful waiting" period for acute HCV patients was rooted in two primary factors: the biology of the virus and the limitations of older therapies.
Statistically, a small subset of patients—historically estimated at around 26%—can spontaneously clear the HCV virus without medical intervention. This phenomenon created a culture of hesitation among clinicians, who sought to avoid unnecessary treatment. Furthermore, the treatments available prior to the modern era of direct-acting antivirals (DAAs) were arduous. Older regimens, such as interferon-based therapies, were associated with severe side effects, prolonged treatment durations, and historically low success rates. Consequently, delaying treatment until an infection was confirmed as "chronic" (lasting longer than six months) was considered a rational approach to patient management.
However, the medical landscape has been transformed by the advent of potent, well-tolerated DAAs. Mudra Kapoor, vice president of Neuroscience, Eyecare, Specialty, and VIO Medical Affairs + Health Impact at AbbVie, emphasizes that the benefit-risk profile of modern treatments makes the "wait-and-see" approach obsolete.
"We no longer have to go through additional steps to check for chronicity or worry about how far back they got the infection," Kapoor noted. "Routine practice needs to get to a point where the minute you diagnose someone as positive for HCV, you treat them. That’s not where we are, but it’s where we need to go."
A Brief Chronology of HCV Treatment Evolution
The journey toward this expanded indication for Maviret is the culmination of nearly two decades of clinical and regulatory advancement:
- Pre-2010s: The "Interferon Era," characterized by injectable therapies with low efficacy and high toxicity, necessitated careful patient selection and delayed initiation to ensure the treatment burden was warranted.
- 2017: The initial approval of Maviret (glecaprevir/pibrentasvir) marked a turning point in the DAA era, offering a pan-genotypic treatment option that was highly effective and required a short, once-daily regimen.
- 2020: International clinical guidance began shifting, officially recommending the prompt treatment of acute HCV to prevent onward transmission and long-term liver damage. Despite these recommendations, the drug’s label remained restricted to chronic cases, leading to administrative hurdles for clinicians attempting to follow the new guidelines.
- 2026: The European Commission approves the expanded indication for Maviret, formally authorizing its use for acute HCV. This regulatory change finally bridges the gap between clinical guidance and patient access.
The Mechanism of Action: How Maviret Works
Maviret is a fixed-dose combination therapy designed to attack the HCV virus at two critical stages of its replication cycle. The efficacy of the drug is derived from its dual-action profile:
- Glecaprevir: This component serves as an NS3/4A protease inhibitor. It functions by blocking the specific enzyme that the virus requires to cleave its polyprotein into the mature, functional proteins necessary for viral replication.
- Pibrentasvir: This component acts as an NS5A inhibitor. It targets a protein essential for the replication of viral RNA and the assembly of new virus particles.
By inhibiting these two distinct targets simultaneously, the therapy achieves a high barrier to resistance and potent antiviral activity. In the Phase 3 M20-350 trial, which served as the clinical foundation for the new approval, 96.2% of patients treated with the eight-week regimen achieved a sustained virologic response (SVR) 12 weeks after completion, confirming the drug’s effectiveness in the acute setting.
Implications for Public Health and Transmission
The most significant consequence of the new label is the potential to curb the spread of the virus. While a patient waits to see if their body will spontaneously clear an acute infection, they remain a source of potential transmission. By treating patients immediately upon diagnosis, the healthcare system can effectively "break the chain" of transmission.
"When you look at the benefit-risk equation today, it would almost be a disservice to patients not to treat them," Kapoor said. "Beyond the individual, we must look at the broader picture, at society, and the socioeconomic benefit you gain by treating this one person."
This perspective aligns with the World Health Organization’s (WHO) 2030 elimination targets. As curative treatments become more accessible, the focus of the global health community has shifted from merely managing chronic cases to aggressive, early-stage intervention and case-finding.
Challenges in the Ecosystem: Access and Equity
Despite the therapeutic success of Maviret, AbbVie acknowledges that regulatory approval is only one piece of the puzzle. The challenge of eliminating Hepatitis C is as much about logistics, policy, and funding as it is about science.
The Access Landscape
AbbVie has taken steps to address affordability through various models. In the United States, the company partnered with Washington state in 2019 to implement a "subscription-style" payment program, which allowed for broader access while providing budget certainty for the state. Internationally, the company signed a voluntary licensing agreement with the Medicines Patent Pool (MPP) in 2018, aimed at increasing access in 99 low- and middle-income countries (LMICs).
However, these efforts have faced scrutiny. Advocacy groups, including Médecins Sans Frontières (MSF), have publicly raised concerns that the drug remains inaccessible in many regions due to pricing structures and patent limitations, suggesting that more robust international cooperation is required to reach the most vulnerable populations.
The Lithuania Model: A Case Study in Success
Lithuania offers a compelling example of how a coordinated effort between industry and government can move the needle on HCV elimination. In 2022, the country launched a national screening program supported by AbbVie, which incentivized general practitioners to conduct antibody testing.
The program resulted in over 75% of the relevant birth cohort being tested within 34 months, and the number of patients treated tripled. Despite this success, researchers have noted that Lithuania still faces hurdles, such as remaining fibrosis-stage restrictions, which must be lifted if the country is to reach the WHO 2030 targets.
Future Outlook: A Call for Global Coordination
The expansion of the Maviret indication is a victory for patient-centric medicine, but as Mudra Kapoor emphasizes, industry effort alone is insufficient. The path to global elimination requires a cohesive "ecosystem" approach.
"It takes more than AbbVie to meet these goals," Kapoor concluded. "We need policymakers to take action, we need payers to take action, and we need everyone to actually want to eliminate HCV."
The shift from reactive to proactive treatment of Hepatitis C represents a critical evolution in infectious disease management. With the diagnostic tools and the curative, direct-acting antivirals now firmly in place, the challenge for the next decade will be moving the focus from the lab to the clinic, and from the individual patient to the global population. The "wait-and-see" era is ending; the era of active elimination has begun.
About the Author
